Thus, in addition to the loss of regulatory influence at enhancers that accompanies CREBBP/P300 inactivation, GC B-cells also lose their ability to directly regulate p53 and BCL6, both of which are integral to GC physiology and DLBCL pathology. Here, CREBBP is linked to diffuse large B-cell lymphoma.